DrugPatentWatch Database Preview
Details for Patent: 9,243,245
» See Plans and Pricing
Which drugs does patent 9,243,245 protect, and when does it expire?
Patent 9,243,245 protects EXONDYS 51 and is included in one NDA.
This patent has sixty-six patent family members in seventeen countries.
Summary for Patent: 9,243,245
| Title: | Means and methods for counteracting muscle disorders |
| Abstract: | The invention provides means and methods for alleviating one or more symptom(s) of Duchenne Muscular Dystrophy and/or Becker Muscular Dystrophy. Therapies using compounds for providing patients with functional muscle proteins are combined with at least one adjunct compound for reducing inflammation, preferably for reducing muscle tissue inflammation, and/or at least one adjunct compound for improving muscle fiber function, integrity and/or survival. |
| Inventor(s): | De Kimpe; Josephus Johannes (Utrecht, NL), Platenburg; Gerard Johannes (Voorschoten, NL), Van Deutekom; Judith Christina Theodora (Dordrecht, NL), Aartsma-Rus; Annemieke (Hoofddorp, NL), Van Ommen; Garrit-Jan Boudewijn (Amsterdam, NL) |
| Assignee: | Academisch Ziekenhuis Leiden (Leiden, NL) BioMarin Technologies B.V. (Leiden, NL) |
| Application Number: | 12/767,702 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Compound; Device; |
Drugs Protected by US Patent 9,243,245
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sarepta Theraps Inc | EXONDYS 51 | eteplirsen | SOLUTION;INTRAVENOUS | 206488-001 | Sep 19, 2016 | RX | Yes | Yes | Start Trial | Start Trial | Y | TREATMENT OF DMD IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING | Start Trial | |||
| Sarepta Theraps Inc | EXONDYS 51 | eteplirsen | SOLUTION;INTRAVENOUS | 206488-001 | Sep 19, 2016 | RX | Yes | Yes | Start Trial | Start Trial | Y | INCREASING PRODUCTION OF FUNCTIONAL DYSTROPHIN PROTEIN IN DMD PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING | Start Trial | |||
| Sarepta Theraps Inc | EXONDYS 51 | eteplirsen | SOLUTION;INTRAVENOUS | 206488-002 | Sep 19, 2016 | RX | Yes | Yes | Start Trial | Start Trial | Y | TREATMENT OF DMD IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,243,245
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| 07119351 | Oct 26, 2007 | |
International Family Members for US Patent 9,243,245
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2008317566 | Start Trial | |||
| Australia | 2009310557 | Start Trial | |||
| Australia | 2009310558 | Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
